Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Expected to Post Quarterly Sales of $4.38 Billion

researchsnappy by researchsnappy
January 14, 2020
in Healthcare Research
0
Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at JPMorgan Chase & Co.
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Teva Pharmaceutical Industries logoAnalysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to report $4.38 billion in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the lowest sales estimate coming in at $4.29 billion and the highest estimate coming in at $4.42 billion. Teva Pharmaceutical Industries posted sales of $4.56 billion in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.9%. The firm is expected to report its next earnings results on Wednesday, February 12th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.28 billion for the current fiscal year, with estimates ranging from $17.19 billion to $17.32 billion. For the next year, analysts expect that the business will post sales of $17.08 billion, with estimates ranging from $16.59 billion to $17.75 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The business had revenue of $4.26 billion during the quarter, compared to analysts’ expectations of $4.25 billion.

Several research firms have commented on TEVA. ValuEngine lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. Gabelli upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Wells Fargo & Co decreased their target price on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a research report on Monday, September 30th. Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They set a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 price target for the company in a report on Tuesday, November 12th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $10.64.

In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 4,310 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the completion of the transaction, the vice president now owns 24,883 shares in the company, valued at $261,022.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.49% of the company’s stock.

A number of institutional investors have recently made changes to their positions in TEVA. Nomura Asset Management Co. Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 16.9% during the second quarter. Nomura Asset Management Co. Ltd. now owns 319,862 shares of the company’s stock worth $2,952,000 after purchasing an additional 46,200 shares during the last quarter. Natixis grew its holdings in shares of Teva Pharmaceutical Industries by 245.0% in the second quarter. Natixis now owns 235,274 shares of the company’s stock worth $2,172,000 after purchasing an additional 167,083 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its stake in Teva Pharmaceutical Industries by 1.0% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 815,921 shares of the company’s stock worth $7,531,000 after buying an additional 8,235 shares during the period. Canada Pension Plan Investment Board purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $6,893,000. Finally, CIBC Asset Management Inc increased its stake in Teva Pharmaceutical Industries by 6.6% in the 3rd quarter. CIBC Asset Management Inc now owns 66,513 shares of the company’s stock worth $458,000 after buying an additional 4,128 shares during the period. 53.53% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries stock opened at $10.12 on Friday. The company has a market cap of $10.89 billion, a price-to-earnings ratio of 3.61, a PEG ratio of 1.07 and a beta of 1.83. The firm’s fifty day moving average is $9.73 and its 200 day moving average is $8.29. The company has a quick ratio of 0.56, a current ratio of 0.89 and a debt-to-equity ratio of 1.62. Teva Pharmaceutical Industries has a 52-week low of $6.07 and a 52-week high of $20.21.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Limitations of the P/E Growth ratio

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)



Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

ANZ-Roy Morgan Consumer Confidence bounces to 107.3

Next Post

Hedge Funds From Pershing to Blue Harbour Win on Activism

Next Post
Hedge Funds From Pershing to Blue Harbour Win on Activism

Hedge Funds From Pershing to Blue Harbour Win on Activism

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com